Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

468.25 -9.07 (-1.90%)
Streaming Delayed Price Updated: 10:38 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
71 72 Next >
News headline image
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today ↗
 
Via Benzinga
News headline image
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock ↗
Vertex just laid claim to an asset that might be very valuable. 
Via The Motley Fool
News headline image
Could This Stock Be the Next Biotech Buyout? ↗
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool
News headline image
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals: Buy, Sell, or Hold? ↗
The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run? 
Via The Motley Fool
News headline image
1 Top Growth Stock to Buy and Hold Forever ↗
This drugmaker looks unstoppable. 
Via The Motley Fool
News headline image
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review ↗
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. 
Via Investor's Business Daily
Topics Economy
News headline image
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
News headline image
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday? ↗
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures... 
Via Benzinga
Topics Economy
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024 ↗
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
News headline image
Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock ↗
Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts. 
Via InvestorPlace
News headline image
Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts ↗
An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack. 
Via InvestorPlace
News headline image
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
News headline image
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
News headline image
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune ↗
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to... 
Via Benzinga
News headline image
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity' ↗
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons 
Via Benzinga
Topics Economy
News headline image
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal ↗
The companies expect the deal to close later this quarter. 
Via Investor's Business Daily
News headline image
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Vertex to Announce First Quarter 2024 Financial Results on May 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy? ↗
This innovative machine rolls on. 
Via The Motley Fool
News headline image
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over 
Via Benzinga
News headline image
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April ↗
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term. 
Via InvestorPlace
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
These companies are close to launching new products that could supercharge revenue. 
Via The Motley Fool
News headline image
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul ↗
These businesses are booming. 
Via The Motley Fool
News headline image
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
Via MarketBeat
Topics ETFs
News headline image
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead ↗
All three companies have very long runways for growth ahead. 
Via The Motley Fool
News headline image
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Meet The "Magnificent Seven" of Healthcare Stocks ↗
The tech sector doesn't have a monopoly on magnificent corporations. 
Via The Motley Fool
News headline image
2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years ↗
Great businesses are here to stay. These are two excellent examples. 
Via The Motley Fool
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.